Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis

B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome virus-2 (SARS-CoV-2) has raised concerns with the coronavirus disease 2019 (COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Asplund Högelin, Klara, Ruffin, Nicolas, Pin, Elisa, Månberg, Anna, Hober, Sophia, Gafvelin, Guro, Grönlund, Hans, Nilsson, Peter, Khademi, Mohsen, Olsson, Tomas, Piehl, Fredrik, Al Nimer, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410640/
https://www.ncbi.nlm.nih.gov/pubmed/34490414
http://dx.doi.org/10.1016/j.isci.2021.103078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410640/
https://www.ncbi.nlm.nih.gov/pubmed/34490414
http://dx.doi.org/10.1016/j.isci.2021.103078

Ejemplares similares